{"id":575731,"date":"2025-09-25T00:00:00","date_gmt":"2025-09-25T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acremd0017-2025-biopharma-immunoglobulin-a-nephropathy-access-reimbursement-access-reimbursement-iga-nephropathy-us\/"},"modified":"2026-03-31T10:24:56","modified_gmt":"2026-03-31T10:24:56","slug":"acremd0017-2025-biopharma-immunoglobulin-a-nephropathy-access-reimbursement-access-reimbursement-iga-nephropathy-us","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acremd0017-2025-biopharma-immunoglobulin-a-nephropathy-access-reimbursement-access-reimbursement-iga-nephropathy-us\/","title":{"rendered":"Immunoglobulin A Nephropathy &#8211; Access &#038; Reimbursement &#8211; Access &#038; Reimbursement &#8211; IgA Nephropathy (US)"},"content":{"rendered":"<p>The U.S. <abbr title=\"immunoglobulin A\">IgA<\/abbr> nephropathy (<abbr title=\" immunoglobulin A nephropathy\">IgAN<\/abbr>) therapy market predominantly comprises supportive treatments such as <abbr title=\"renin-angiotensin-aldosterone system\">RAAS<\/abbr> inhibitors, <abbr title=\"sodium-glucose co-transporter-2\">SGLT-2<\/abbr> inhibitors, immunosuppressants, and\/or diuretics. The <abbr title=\"Food and Drug Administration\">FDA<\/abbr>\u2019s acceptance of the surrogate clinical trial endpoint \u201creduction in proteinuria\u201d has enabled early approval of therapeutic agents labeled for <abbr title=\" immunoglobulin A nephropathy\">IgAN<\/abbr>: Calliditas Therapeutics\u2019 Tarpeyo (<abbr title=\"delayed-release\">DR<\/abbr>-budesonide), Travere Therapeutics\u2019 Filspari (sparsentan), and Novartis\u2019s Fabhalta (iptacopan). Because all approved targeted therapies are expensive, payers usually restrict their access to high-risk patients. Several therapies are also in late-phase development for <abbr title=\" immunoglobulin A nephropathy\">IgAN<\/abbr>. This report examines the prescribing and reimbursement environment for key current and emerging <abbr title=\" immunoglobulin A nephropathy\">IgAN<\/abbr> agents in the United States according to surveyed nephrologists and <abbr title=\"managed care organization\">MCO<\/abbr> <abbr title=\"pharmacy director\">PD<\/abbr>s \/ <abbr title=\"medical director\">MD<\/abbr>s. It explores how physicians and payers perceive current and emerging <abbr title=\" immunoglobulin A nephropathy\">IgAN<\/abbr> therapies and the reimbursement dynamics that will promote or restrict market access to the agents.<\/p>\n<p><b>Questions answered<\/b><\/p>\n<ul class=\"round-bullets\">\n<li>What is the state of coverage of Tarpeyo, Filspari, and Fabhalta? What restrictions do payers impose, and how do market access dynamics influence surveyed nephrologists\u2019 prescribing?<\/li>\n<li>What is the state of coverage for <abbr title=\" immunoglobulin A nephropathy\">IgAN<\/abbr> diagnostics (e.g., kidney biopsy, blood-based biomarkers such as <abbr title=\"estimated glomerular filtration rate\">eGFR<\/abbr> and <abbr title=\"urine protein:creatinine ratio\">UPCR<\/abbr>), and how are physicians using them? What factors will drive preferential use and coverage?<\/li>\n<li>How receptive are payers to emerging drugs (e.g., Vera Therapeutics\u2019 <abbr title=\"a proliferation-inducing ligand\">APRIL<\/abbr>\/<abbr title=\"B-cell-activating factor\">BAFF<\/abbr> inhibitor atacicept, Novartis\u2019s endothelin receptor antagonist atrasentan)? What points of differentiation are \/ will be most compelling to nephrologists and payers of new therapies for <abbr title=\" immunoglobulin A nephropathy\">IgAN<\/abbr>?<\/li>\n<\/ul>\n<p><strong>Content highlights<\/strong><\/p>\n<p><strong>Geography:<\/strong> United States<\/p>\n<p><strong>Primary research:<\/strong> Survey of 100 U.S. nephrologists; survey of 30 U.S. managed care organization (<abbr title=\"managed care organization\">MCO<\/abbr>) pharmacy and medical directors (<abbr title=\"pharmacy director\">PD<\/abbr>s\/<abbr title=\"medical director\">MD<\/abbr>s)<\/p>\n<p><strong>Key drugs covered: <\/strong>Tarpeyo, Filspari, Fabhalta, <abbr title=\"renin-angiotensin-aldosterone system\">RAAS<\/abbr> inhibitors, <abbr title=\"sodium-glucose co-transporter-2\">SGLT-2<\/abbr> inhibitors, iptacopan, sibeprenlimab, zigakibart, atacicept, povetacicept, atrasentan<\/p>\n<p><strong>Production description<\/strong><\/p>\n<p>Leveraging Clarivate\u2019s proprietary data sources and surveys with physicians and payers, Access &#038; Reimbursement provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of payer policy on physician prescribing behavior in the United States. Through detailed analyses of drug coverage, restriction policies, and contracting, as well as payer and prescriber perspectives on key marketed drugs and their receptivity to emerging therapies, this report enables you to:<\/p>\n<ul>\n<li>Identify and learn how to overcome roadblocks to market access to best position your brand.<\/li>\n<li>Identify key stakeholders and reimbursement drivers and assess the impact that reimbursement decisions have on treatment selection.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-575731","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/575731","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/575731\/revisions"}],"predecessor-version":[{"id":577512,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/575731\/revisions\/577512"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=575731"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}